Kirk. J M JM; Trainer. P J PJ; Majrowski. W H WH; Murphy. J J; Savage. M O MO; Besser. G M GM
Giving the growth‑hormone‑releasing peptide (GHRH‑1‑29, also known as sermorelin) twice a day for a year helped short, pre‑pubertal kids grow faster, but the boost stopped once they stopped the injections and their growth returned to normal. Blood sugar and insulin went up during treatment, and overall growth‑hormone levels actually fell over time.
Banks. William A WA; Morley. John E JE; Farr. Susan A SA; Price. Tulin O TO; Ercal. Nuran N; Vidaurr...
In mice that age quickly, blocking the hormone that tells the pituitary to release growth hormone (using a drug called MZ-5-156) raised telomerase activity, lowered some brain oxidative stress, improved balance and short‑term memory, cut tumor rates, and added about two months to average lifespan, though it didn’t change the longest lives.
Scientists created a super‑sensitive urine test that can spot growth‑hormone‑releasing peptides like sermorelin at very low levels (0.5 ng/mL). The method uses tiny‑scale liquid chromatography and high‑resolution mass spectrometry, and it meets anti‑doping lab standards.
Volakaki. Aspasia-Athina AA; Lafkas. Daniel D; Kassi. Eva E; Schally. Andrew V AV; Papavassiliou. At...
The study shows that blocking the hormone GHRH with a drug called JMR-132 slows down the growth of lung cancer cells by raising a protein called p21, which tells cells to stop dividing. If p21 is removed, the drug no longer works, meaning the anti‑cancer effect depends on p21. Similar results were seen in colon cancer cells and normal bone cells.
Thomas. Andreas A; Thilmany. Sam S; Hofmann. Amelie A; Thevis. Mario M
The study shows a lab method that can reliably spot small peptide drugs like sermorelin in blood, using high‑resolution mass spectrometry and a simple extraction step. It proves that blood tests can catch these peptides more easily than urine tests.
Chatzistamou. I I; Schally. A V AV; Varga. J L JL; Groot. K K; Armatis. P P; Busto. R R; Halmos. G G
In mice with human ovarian cancer cells, drugs that block the hormone that normally tells the pituitary to release growth hormone (GHRH) shrank tumors by about 60‑70%, while a somatostatin‑like drug also cut tumor size and lowered a growth‑promoting protein called IGF‑I.
Adams. E F EF; Law. H H; Buchfelder. M M; Fahlbusch. R R; Lightman. S S; Levy. A A
The study shows that many pituitary tumors can make GHRH messenger RNA, but blocking GHRH doesn’t lower their natural growth‑hormone release, meaning the tumors aren’t driven by their own GHRH. The antagonist only stops the effect of added GHRH, not the baseline hormone output. For biohackers, this means GHRH‑based tools like sermorelin work the same regardless of any internal GHRH production, and GHRH blockers won’t suppress GH in normal or tumor settings.
Achermann. J C JC; Brook. C G CG; Hindmarsh. P C PC
In adults who survived childhood brain tumors and got radiation to the head, their pituitary glands don’t release much growth hormone (GH) even when given low or high doses of a GHRH peptide (like sermorelin). The GH spikes are far smaller than in healthy people, showing the gland’s reduced sensitivity. This suggests that radiation‑induced damage limits how well GHRH can boost GH.
Grunt. J A JA; Schwartz. I D ID; Buchanan. C C; Howard. C P CP
A tiny study gave a growth‑hormone‑releasing peptide (sermorelin) to seven kids who were unusually short but had normal growth‑hormone levels. Five of them kept taking it for two years and grew better, while two stopped after a year because they didn’t see enough growth.
Barabutis. Nektarios N; Siejka. Agnieszka A; Schally. Andrew V AV
The study shows that growth hormone‑releasing hormone (the same family as sermorelin) can make lung cancer cells grow faster by turning on a signaling pathway (ERK) and boosting an enzyme called inducible nitric oxide synthase, which is linked to inflammation and cancer. Blocking GHRH with a specific antagonist stopped these effects, suggesting that GHRH activity might have pro‑tumor risks.
Rick. Ferenc G FG; Schally. Andrew V AV; Szalontay. Luca L; Block. Norman L NL; Szepeshazi. Karoly K...
In lab tests and mouse experiments, a drug that blocks the hormone that normally tells the pituitary to release growth hormone (called a GHRH antagonist) slowed down the growth of a type of prostate cancer that doesn't need male hormones. The drug cut tumor size by about 60% and turned off two key cell‑growth pathways (ERK and Akt).
Beccaria. L L; Benzi. F F; Sanzari. A A; Bosio. L L; Brambilla. P P; Chiumello. G G
The study shows that people with Prader‑Labhardt‑Willi syndrome have a weak growth‑hormone (GH) response to both clonidine and a combination of GHRH plus a cholinergic drug, especially if they are older or have more body fat. This suggests that obesity and age can blunt the effectiveness of GH‑stimulating treatments like sermorelin.
Rodrigues-Dos-Santos. Karina K; Soares. Gabriela M GM; Guimarães. Dimitrius S P S F DSPSF; Ara&...
A lab study looked at a GHRH‑like peptide called MR‑409 (similar to sermorelin) on insulin‑producing cells that were stressed in a way that mimics type‑2 diabetes. The peptide didn’t stop the stress itself, but the cells treated with it showed less oxidative damage and survived better.
Cui. Tengjiao T; Jimenez. Joaquin J JJ; Block. Norman L NL; Badiavas. Evangelos V EV; Rodriguez-Meno...
A study tested two synthetic versions of growth‑hormone‑releasing hormone (MR‑409 and MR‑502) and found they make human skin cells grow faster and survive stress better. In mice, applying MR‑409 to wounds helped the cuts close quicker and left less scar tissue. The effects rely on the ERK and AKT signaling pathways, not on the usual IGF‑1 route.
Researchers used NMR to map the shape of the hormone secretin in a special solvent and found it forms two short helices with irregular ends. This shape looks a lot like the active part of growth‑hormone‑releasing factor, which is the same sequence used in the peptide sermorelin.
Heinrich. Elmar E; Schally. Andrew V AV; Buchholz. Stefan S; Rick. Ferenc G FG; Halmos. Gabor G; Mil...
In mice with human prostate cancer, a new drug that blocks the hormone that normally tells the pituitary to release growth hormone (a GHRH antagonist called MZ-J-7-138) shrank the tumors in a dose‑dependent way, especially at the highest dose. The drug also lowered two growth‑promoting proteins in the tumors, IGF‑II and VEGF.
In mice, a synthetic molecule that blocks growth‑hormone‑releasing hormone (called MIA‑690) made the animals eat more and gain weight. It did this by changing brain chemicals that control hunger and by lowering a fat‑signal hormone (leptin). The related GHRH‑activating molecule (MR‑409) did not change eating or weight.
Sopwith. A M AM; Penny. E S ES; Grossman. A A; Savage. M O MO; Besser. G M GM; Rees. L H LH
The study measured a natural growth‑hormone‑releasing factor (hGRF) in people whose brain’s hormone‑release center was damaged and found that after a normal breakfast their blood levels still rose, showing the body can make this peptide outside the brain. This suggests hGRF (and its drug version, sermorelin) might act in peripheral tissues, not just the brain.
Kovacs. M M; Gulyas. J J; Bajusz. S S; Schally. A V AV
The study shows that the standard growth‑hormone‑releasing peptide (sermorelin) works much better when given intravenously than under the skin, while several experimental agmatine‑modified versions are dramatically stronger when injected subcutaneously. This means the usual sub‑Q sermorelin shots many biohackers use are likely far less effective than expected, and the big gains seen with the new analogs are due to better skin absorption, not a different species response.
Bagno. Luiza L LL; Kanashiro-Takeuchi. Rosemeire M RM; Suncion. Viky Y VY; Golpanian. Samuel S; Kara...
In a pig model of heart attacks, daily injections of a growth‑hormone‑releasing hormone agonist (MR‑409) shrank the scar tissue and improved the heart's ability to stretch, but it didn't boost overall pumping function. The drug was safe and easy to give under the skin.